Patents by Inventor Dirk Elewaut
Dirk Elewaut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230218714Abstract: The present invention relates to diagnostic methods to assess the presence of quorum sensing molecules (QSM), preferably peptides (QSPs), that influence muscle wasting in humans. The present invention furthermore relates to the use of the knowledge obtained by the diagnostic method in order to influence muscle wasting diseases in animals and human, by for example providing bacteria that produce beneficial QSMs or non-harmful QSMs, providing antagonists for harmful QSMs and the like.Type: ApplicationFiled: November 6, 2020Publication date: July 13, 2023Inventors: Bart DE SPIEGELEER, Anton DE SPIEGELEER, Evelien WYNENDAELE, Dirk ELEWAUT, Nele VAN DEN NOORTGATE
-
Patent number: 10723750Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.Type: GrantFiled: November 14, 2016Date of Patent: July 28, 2020Assignees: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZWInventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
-
Patent number: 10479832Abstract: The disclosure provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyper-resorption of bone and/or enhanced activation of osteoclasts.Type: GrantFiled: March 30, 2015Date of Patent: November 19, 2019Assignees: Universiteit Gent, VIB VZWInventors: Dirk Elewaut, Els Louagie, Nele Juchtmans
-
Publication number: 20190343893Abstract: The present invention relates to the field of inflammation-associated disorders or conditions, more particularly to gut inflammation and/or joint inflammation, even more particularly to spondyloarthritis. Provided herein are means and methods to treat, prevent and/or reduce the severity of inflammation-associated disorders or conditions in a subject in need thereof.Type: ApplicationFiled: June 23, 2017Publication date: November 14, 2019Inventors: Jeroen Raes, Dirk Elewaut, Raul Yhossef Tito-Tadeo, Geert Huys, Lars Vereecke
-
Publication number: 20190256541Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.Type: ApplicationFiled: November 14, 2016Publication date: August 22, 2019Applicants: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZWInventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
-
Publication number: 20170290885Abstract: The invention relates to a method for treating joint inflammation. More particularly, the invention relates to a method for treating joint disease involving the inhibition or inactivation of growth differentiation factor 15 (GDF15) in an individual.Type: ApplicationFiled: September 29, 2015Publication date: October 12, 2017Inventors: Dirk ELEWAUT, Stijn LAMBRECHT
-
Publication number: 20170129953Abstract: The disclosure provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyper-resorption of bone and/or enhanced activation of osteoclasts.Type: ApplicationFiled: March 30, 2015Publication date: May 11, 2017Applicants: Universiteit Gent, VIB VZWInventors: Dirk Elewaut, Els Louagie, Nele Juchtmans
-
Patent number: 9321796Abstract: This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 20, 2013Date of Patent: April 26, 2016Assignee: Universiteit GentInventors: Dirk Elewaut, Nora Pauwels, Sandrine Aspeslagh, Serge Van Calenbergh
-
Publication number: 20150210728Abstract: This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 20, 2013Publication date: July 30, 2015Inventors: Dirk Elewaut, Nora Pauwels, Sandrine Aspeslagh, Serge Van Calenbergh
-
Patent number: 9086419Abstract: In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.Type: GrantFiled: February 17, 2010Date of Patent: July 21, 2015Assignee: Universiteit GentInventors: Stijn Lambrecht, Dieter Deforce, Dirk Elewaut, August Verbruggen
-
Publication number: 20130273080Abstract: Methods of delivering a cargo moiety to a cell is provided that include contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided herein.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Dirk Elewaut, Els Louagie, Peter Delputte
-
Patent number: 8532362Abstract: The present invention provides a scoring system to monitor natural or drug-modified disease progression in erosive inter-phalangeal finger joint osteoarthrits and the use of said scoring system to identify and value drugs with anticatabolic and/or repair promoting potential.Type: GrantFiled: July 24, 2009Date of Patent: September 10, 2013Assignee: Ghent UniversityInventors: August Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, Dirk Elewaut
-
Patent number: 8466278Abstract: This invention relates to novel ?-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.Type: GrantFiled: September 22, 2009Date of Patent: June 18, 2013Assignee: Arcarios B.V.Inventors: Dirk Elewaut, August Lodewijk Verbruggen
-
Publication number: 20110300562Abstract: In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Applicant: UNIVERSITEIT GENTInventors: Stijn Lambrecht, Dieter Deforce, Dirk Elewaut, August Verbruggen
-
Publication number: 20110300548Abstract: The present invention relates to GDF15 as a molecular marker in in vitro assays determining phenotypic stability of articular chondrocytes and predicting the outcome of chondrocyte transplantation.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Applicant: Universiteit GentInventors: Stijn Lambrecht, Dieter Deforce, Dirk Elewaut, August Verburggen
-
Publication number: 20110263948Abstract: The present invention provides a scoring system to monitor natural or drug-modified disease progression in erosive inter-phalangeal finger joint osteoarthrits and the use of said scoring system to identify and value drugs with anticatabolic and/or repair promoting potential.Type: ApplicationFiled: July 24, 2009Publication date: October 27, 2011Applicant: GHENT UNIVERSITYInventors: August Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, Dirk Elewaut
-
Publication number: 20110172182Abstract: This invention relates to novel ?-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.Type: ApplicationFiled: September 22, 2009Publication date: July 14, 2011Applicant: ARCARIOS B.V.Inventors: Dirk Elewaut, August Lodewijk Verbruggen
-
Patent number: 7959907Abstract: The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.Type: GrantFiled: February 20, 2008Date of Patent: June 14, 2011Assignees: VIB VZW, Universiteit GentInventors: Peter Brouckaert, Dirk Elewaut, Leander Huyghe
-
Publication number: 20100330036Abstract: The invention relates generally to the field of tissue engineering. More particularly, the present invention relates to methods for identifying a population of cells suitable for the repair of connective tissue, including cartilage. The invention further provides methods and compositions related to the generation of a population of cells suitable for the repair of cartilage, in particular in the repair of cartilage degeneration associated with osteoarthritis. Methods of using said cells thus identified or thus generated, in methods to extend the period of cell manipulation, i.e. to increase the yield of cells suitable in the aforementioned methods, are also provided by the present invention.Type: ApplicationFiled: October 20, 2008Publication date: December 30, 2010Applicant: UNIVERSITEIT GENTInventors: Stijn Lambrecht, Dieter Deforce, Dirk Elewaut, August Verbruggen
-
Publication number: 20100166697Abstract: The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.Type: ApplicationFiled: February 20, 2008Publication date: July 1, 2010Inventors: Peter Brouckaert, Dirk Elewaut, Leander Huyghe